GoodRx Holdings Inc.
04/24/2026 | Press release | Distributed by Public on 04/24/2026 14:29
Management Change/Compensation (Form 8-K)
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
Chief Accounting Officer Appointment
On April 23, 2026, the Board of Directors (the "Board") of GoodRx Holdings, Inc. (the "Company") appointed Thomas
Chan, Vice President, Corporate Controller of the Company as the Company's Chief Accounting Officer and designated Mr.
Chan as the principal accounting officer of the Company, in each case effective immediately.
Mr. Chan, 40, joined the Company in October 2020 and has served in various controllership and financial reporting
roles, including as our Vice President, Corporate Controller from February 2024 to April 2026; Vice President, Accounting &
Reporting from May 2023 to February 2024; Vice President, Financial Reporting & Quality from July 2022 to May 2023; and
other accounting roles of increasing responsibility from October 2020 to July 2022. Prior to joining the Company, Mr. Chan
served in various audit and assurance roles at Deloitte & Touche, LLP since July 2011, most recently as an Audit &
Assurance Senior Manager. Mr. Chan holds a B.A. in Business Administration, with an emphasis in accounting, from
California State University, Fullerton, and is a Certified Public Accountant in the State of California.
In connection with his appointment, the Board approved an annual base salary increase to $310,000, with a target
annual bonus of 40% of his base salary. In addition, Mr. Chan will be granted (i) a restricted stock unit award ("RSU Award")
having an aggregate value of $131,250 and (ii) a performance-based restricted stock unit award ("PSU Award") having an
aggregate value of $43,750 under the Company's 2020 Incentive Award Plan. We currently expect each award will be
granted on the first trading day of the first "open window" that occurs following the Effective Date.
The number of shares of the Company's Class A common stock subject to the RSU Award and PSU Award will be
determined based on the closing share price over the last 30 calendar days preceding the applicable grant date. The RSU
Award will vest ratably in twelve equal quarterly installments, with the first vesting occurring on August 15, 2026, subject to
Mr. Chan's continued employment through each vesting date. The PSU Award will vest in three equal installments, with one-
third vesting on March 3, 2027, and one-third vesting on each of the first and second anniversaries thereof, subject to the
achievement of applicable performance goals and continued employment through each vesting date.
There are no transactions in which the Company is a party and in which Mr. Chan has a material interest subject to
disclosure under Item 404(a) of Regulation S-K. There are no family relationships between Mr. Chan and any of the
Company's current or former directors or executive officers.
Mr. Chan has also entered into the Company's standard indemnification agreement for directors and officers, the form of
which was previously filed by the Company as Exhibit 10.1 to the Registration Statement on Form S-1/A (File No.
333-248465) initially filed by the Company with the Securities and Exchange Commission on September 14, 2020.
GoodRx Holdings Inc. published this content on April 24, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 24, 2026 at 20:30 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]